Hsiu-Li Lin1, Hsiu-Chen Lin2,3, Yuan-Fu Tseng1, Jane Chen-Jui Chao4,5, Chien-Yeh Hsu6. 1. a Department of Neurology , Sijhih Cathay General Hospital , New Taipei City , Taiwan. 2. b Department of Pediatrics, School of Medicine, College of Medicine , Taipei Medical University , Taipei , Taiwan. 3. c Department of Laboratory Medicine , Taipei Medical University Hospital , Taipei , Taiwan. 4. d School of Nutrition and Health Sciences, College of Nutrition , Taipei Medical University , Taipei , Taiwan. 5. e Nutrition Research Center , Taipei Medical University Hospital , Taipei , Taiwan. 6. f Department of Information Management , National Taipei University of Nursing and Health Sciences , Taipei , Taiwan.
Abstract
OBJECTIVES: We investigated the association of thiazolidinedione and its dose effect with the risk of Parkinson's disease (PD) in patients with diabetes mellitus (DM). METHODS: This study enrolled 38,521 patients with newly-diagnosed DM, between 2001 and 2013, and compared them to the matched subjects without DM. The hazard ratios (HRs) for PD were compared between the thiazolidinedione-treated and non-thiazolidinedione-treated groups of the study cohort, and between subgroups who received different cumulative dosages of thiazolidinedione. RESULTS: We observed that 544 (1.4%) patients developed PD during the follow-up median duration of 6.2 years in patients with newly-diagnosed DM or had a higher risk for PD than patients without DM (HR = 1.150). In the study cohort, the risk of PD was significantly lower in the thiazolidinedione-treated group (HR = 0.399) compared to the non-thiazolidinedione-treated group. Thiazolidinedione reduced the risk of PD in a dose-dependent manner, with HRs ranging from 0.613 to 0.081 with defined daily doses of 0-90 to >720, respectively. CONCLUSIONS: Thiazolidinedione use was associated with a significantly reduced risk of PD in patients with newly-diagnosed DM. Further studies to elucidate the common mechanism of PD and DM may provide novel therapies for these two diseases. Key messages Newly-diagnosed diabetes mellitus slightly increases the risk for Parkinson's disease. Thiazolidinedione is associated with a lower risk of Parkinson's disease in a dose-dependent manner in patients with newly-diagnosed diabetes mellitus.
OBJECTIVES: We investigated the association of thiazolidinedione and its dose effect with the risk of Parkinson's disease (PD) in patients with diabetes mellitus (DM). METHODS: This study enrolled 38,521 patients with newly-diagnosed DM, between 2001 and 2013, and compared them to the matched subjects without DM. The hazard ratios (HRs) for PD were compared between the thiazolidinedione-treated and non-thiazolidinedione-treated groups of the study cohort, and between subgroups who received different cumulative dosages of thiazolidinedione. RESULTS: We observed that 544 (1.4%) patients developed PD during the follow-up median duration of 6.2 years in patients with newly-diagnosed DM or had a higher risk for PD than patients without DM (HR = 1.150). In the study cohort, the risk of PD was significantly lower in the thiazolidinedione-treated group (HR = 0.399) compared to the non-thiazolidinedione-treated group. Thiazolidinedione reduced the risk of PD in a dose-dependent manner, with HRs ranging from 0.613 to 0.081 with defined daily doses of 0-90 to >720, respectively. CONCLUSIONS:Thiazolidinedione use was associated with a significantly reduced risk of PD in patients with newly-diagnosed DM. Further studies to elucidate the common mechanism of PD and DM may provide novel therapies for these two diseases. Key messages Newly-diagnosed diabetes mellitus slightly increases the risk for Parkinson's disease. Thiazolidinedione is associated with a lower risk of Parkinson's disease in a dose-dependent manner in patients with newly-diagnosed diabetes mellitus.
Entities:
Keywords:
Diabetes mellitus; National Health Insurance Research Dataset; Parkinson’s disease; thiazolidinedione
Authors: Oluwanifemi Shola-Dare; Shelby Bailess; Carlos C Flores; William M Vanderheyden; Jason R Gerstner Journal: Int J Mol Sci Date: 2021-11-25 Impact factor: 5.923